Top 10 Medical AI Stocks on Wall Street’s Radar

6. Relay Therapeutics Inc (NASDAQ:RLAY)

Number of Hedge Fund Holders: 30

Relay Therapeutics Inc. (NASDAQ:RLAY) is a leading clinical-stage precision medicines firm focused on cancer treatments. The company uses AI and ML for drug discovery, combining computational power with new-age experimental data to offer insights into protein motion and function and identify candidates that can be transformed into novel therapies.

On January 17th, Barclays assigned a “Buy” rating on the stock with a $17 target price. Barclays analysts said Eli Lilly’s (NYSE:LLY) upcoming acquisition of Scorpion Therapeutic will likely have a positive impact on Relay Therapeutics Inc (NASDAQ:RLAY) due to their similar competitive PI3Kalpha programs in breast cancer. The brokerage highlighted that Relay’s RLY-2608 is ahead in clinical development, and Scorpion’s $2.5 billion acquisition value implies an upside in Relay shares.